Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their
low incidence, it is challenging to conduct clinical trials and develop treatment guidelines …

Salivary gland cancers (SGCs), categorized as head and neck cancers (HNCs), constitute
about 6% of head and neck cancer diagnoses based on estimate by American Head and …

Introduction: Salivary gland carcinomas (SGC) are histologically diverse cancers and next-
generation sequencing (NGS) to identify key molecular targets is an important aspect in the …

Aim To evaluate the potential use of Cephaeline as a therapeutic strategy to manage
mucoepidermoid carcinomas (MEC) of the salivary glands. Material and Methods UM‐HMC …

Drug resistance remains a major obstacle in the treatment of mucoepidermoid carcinomas
(MEC) leading to tumor recurrence, disease progression, and metastasis. Emerging …

Salivary gland tumors (SGTs) comprise a group of rare neoplasms. Locally aggressive,
recurrent and/or metastatic SGTs are notorious for their resistance to systemic therapy …

Mesenchymal stem cells (MSCs) are emerging as vehicles for anti-tumor cytotherapy;
however, investigation on its efficacy to target a specific cancer stem cell (CSC) population …

Post-translational modification of histones is the crucial event that affect many tumor-specific
traits. A diverse type of histone modifications had been reported in different cancers with …

Objectives Mucoepidermoid carcinoma (MEC) is the most common type of salivary gland
malignancy. Advanced or high-grade MECs are refractory to chemotherapy, often leading to …

Tumor resistance remains an obstacle to successfully treating oral squamous cell carcinoma
(OSCC). Cisplatin is widely used as a cytotoxic drug to treat solid tumors, including …